Welcome to our dedicated page for Avantor SEC filings (Ticker: AVTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Avantor's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Avantor's regulatory disclosures and financial reporting.
Avantor, Inc. director reported acquiring additional company stock. On December 5, 2025, the insider received 8,106 restricted stock units of Avantor common stock, which vest on May 6, 2026, and are held directly. On the same date, the insider also purchased 350,000 shares of Avantor common stock at a weighted average price of $11.09 per share through a limited liability company, reported as indirectly owned.
The share purchases were executed in multiple trades at prices ranging from $10.98 to $11.21 per share. The reporting person states they will provide full trade-by-trade pricing details upon request and disclaims beneficial ownership of the indirectly held securities except to the extent of any pecuniary interest.
Avantor, Inc. reported that one of its directors filed an initial insider ownership statement effective 12/05/2025. The report indicates that this director does not beneficially own any Avantor securities, including both non-derivative shares and derivative instruments such as options or warrants. The filing is made by a single reporting person on an individual basis and includes a power of attorney authorizing an attorney-in-fact to sign on the reporting person’s behalf.
Avantor, Inc. announced that its Board of Directors has elected Sanjeev Mehra as a director, with an initial term running until the company’s 2026 Annual Meeting of Stockholders. The Board determined he meets the independence standards of the New York Stock Exchange and the Securities Exchange Act of 1934.
Mehra, age 66, is Co‑Founder and Managing Partner of Periphas Capital and previously held senior roles at Goldman Sachs from 1986 to 2017, including Partner and Vice Chairman of the Global Private Equity business. He currently serves on the board of OPENLANE, Inc.
As a non‑employee director, he will receive standard compensation: an annual cash retainer of $95,000, prorated for 2025, and a grant of restricted stock units with a grant date fair value of $210,000, also prorated, vesting in full one year from grant subject to continued service. Avantor also issued a press release about his election, furnished as an exhibit.
Avantor, Inc. (AVTR) disclosed that a reporting person who serves as both President and CEO and a director acquired common stock in the company. On 11/17/2025, this insider purchased 87,500 shares of Avantor common stock at a price of $11.35 per share. Following this open-market purchase, the insider beneficially owns 283,424 shares, held directly.
T. Rowe Price Investment Management, Inc. filed Amendment No. 7 to Schedule 13G reporting beneficial ownership of 32,928,415 shares of Avantor, Inc. common stock, representing 4.8% of the class as of 09/30/2025.
The filer reports sole voting power over 32,838,902 shares and sole dispositive power over 32,928,415 shares, with no shared voting or dispositive power. The filing certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Avantor (AVTR) reported insider equity awards for its EVP, Chief Operating Officer. On November 10, 2025, the officer received 17,391 restricted stock units at $0 and 47,058 stock options with a $11.5 exercise price, expiring November 10, 2035.
Both the RSUs and options vest in two equal annual installments beginning on November 10, 2026. Following these awards, the officer directly beneficially owned 17,391 shares and 47,058 derivative securities.
Avantor (AVTR) insider filing: An Avantor executive serving as EVP, Chief Operating Officer filed a Form 3 initial statement of beneficial ownership. The filing reports no securities are beneficially owned as of the event date 11/10/2025. The document includes an Exhibit 24 power of attorney and was signed by an attorney‑in‑fact.
Avantor (AVTR) appointed Mary Blenn as Executive Vice President and Chief Operating Officer. Her compensation includes a $500,000 annual base salary and an annual cash bonus target of 75% of base salary, pro‑rated for 2025.
The Offer Letter provides an initial equity grant with a target grant date fair value of $5,000,000: $400,000 at start in 2025 (50% RSUs, 50% stock options, vesting ratably over two years) and the remainder in February 2026 (25% RSUs, 25% options, 50% PSUs; RSUs/options vest ratably over three years and PSUs cliff vest based on 2026–2029 performance). Beginning in 2028, she will be eligible for a long‑term incentive target of $2,300,000.
The filing also corrects the CEO’s education disclosure: Emmanuel Ligner holds a Licence and Maitrise in Commerce from Université de Savoie. In addition, effective November 6, 2025, director Gregory Lucier was appointed to the Compensation & Human Resources Committee and the Nominating & Governance Committee.
Arcutis Biotherapeutics received a Rule 144 notice for a planned sale of up to 29,131 shares of common stock, with an aggregate market value of $732,925.88. The filing lists Merrill as broker and indicates sales on NASDAQ with an approximate sale date of 11/06/2025.
The shares to be sold were acquired via restricted share vests on 05/16/2024 (17,856 shares) and 10/01/2024 (11,275 shares). The notice also shows 122,492,192 shares outstanding as context. In the past three months, the filer sold 4,504 shares for $90,262.86 on 10/02/2025. Form 144 is a notice of proposed sales by an affiliate or other holder under the rule’s volume and manner-of-sale conditions.
Avantor (AVTR) Form 4: A company director reported buying 100,000 shares of common stock on 10/30/2025 at $11.25 per share (transaction code P). Following the trade, reported holdings are 300,000 shares held indirectly by a trust and 58,111 shares held directly.
The footnote states the reporting person disclaims beneficial ownership of shares held by the trust except to the extent of his pecuniary interest.